NovaBridge Biosciences
NovaBridge Biosciences (NBP) Revenue
Annual & quarterly revenue history · segment & region breakdown
NBP · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsNovaBridge Biosciences trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2017 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | — |
| 2024-12-31 | $0.00B | -$0.00B | -100.00% |
| 2023-12-31 | $0.00B | +$0.02B | — |
| 2022-12-31 | $-0.01B | -$0.10B | -112.15% |
| 2021-12-31 | $0.09B | -$1.45B | -94.29% |
| 2020-12-31 | $1.54B | +$1.51B | +5042.23% |
| 2019-12-31 | $0.03B | -$0.02B | -44.22% |
| 2018-12-31 | $0.05B | +$0.04B | +377.40% |
| 2017-12-31 | $0.01B | — | — |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income NovaBridge Biosciences receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
NovaBridge Biosciences reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from NovaBridge Biosciences's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
NBP revenue · 4 questionsNBP's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · NovaBridge Biosciences SEC filings · GAAP · NovaBridge Biosciences SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026